NutriEV science in focus: Rising potential of plant-derived extracellular vesicles

NutriEV was proudly represented at TURSEV-26 by its Scientific Coordinator, Professor Seppo Vainio (University of Oulu), who was invited as a plenary speaker at the 2nd Extracellular Vesicles Conference held at Middle East Technical University in Ankara, Türkiye. During his keynote lecture, “High Tech Return to Nature via the Garden of EVe,” Professor Vainio presented the NutriEV vision, exploring how extracellular vesicles can unlock nature-inspired solutions for precision diagnostics, nutrition and next-generation therapeutic innovation.

The meeting demonstrated how rapidly extracellular vesicle (EV) research is evolving from a largely exploratory biological field into a mature translational discipline with growing clinical, industrial, and societal impact. Bringing together more than 325 participants from 20 countries and featuring 125 scientific contributions, the meeting provided a comprehensive overview of the current state and future direction of EV science.

A recurring message throughout the conference was that EVs have emerged as one of the most promising biological platforms for understanding intercellular communication and developing next-generation diagnostics and therapeutics. Researchers from academia, hospitals, biotechnology companies, and clinical laboratories presented advances ranging from fundamental mechanisms of EV biogenesis and cargo sorting to industrial-scale manufacturing and clinical applications.

Advancing cell – free therapies

One of the strongest themes was the clinical translation of mesenchymal stromal cell-derived EVs (MSC-EVs). Bernd Giebel and others highlighted the growing evidence that many of the beneficial effects previously attributed to stem-cell therapies may in fact be mediated by the EVs secreted by these cells.

Significant attention was devoted to overcoming manufacturing and quality-control challenges, with new approaches for producing standardized, GMP-compliant EV products suitable for future therapeutic applications. The field is increasingly moving toward cell-free therapies that may offer many advantages over conventional cell transplantation approaches.

EVs driving the future of precision diagnostics

The conference also showcased remarkable progress in EV-based diagnostics. Numerous studies demonstrated how EVs can function as liquid biopsies, carrying molecular information that reflects the physiological and pathological state of their cells of origin. Researchers presented novel biomarkers for Parkinson’s disease, multiple sclerosis, neuroblastoma, leukemia, colorectal cancer, breast cancer, pancreatic cancer, ovarian cancer, and lung cancer.

Advanced lipidomics, glycomics, transcriptomics, and metabolomics analyses revealed disease-associated EV signatures that may eventually enable earlier diagnosis and more precise patient stratification. Several groups combined EV-derived molecular data with artificial intelligence and machine-learning approaches, illustrating the growing convergence of systems biology and computational medicine.

Unlocking new insights into neurological disorders

Neuroscience represented another major focus area. Plenary lectures demonstrated how EVs participate in communication between neurons, oligodendrocytes, astrocytes, and other neural cells. Studies revealed how EV-mediated signaling contributes to synaptic regulation, neuronal maintenance, and neuroinflammation.

New findings in Parkinson’s disease, glioblastoma, stroke, retinal degeneration, spinal cord injury, and dementia highlighted the increasing recognition that EVs play fundamental roles in both healthy brain function and neurological disease. These discoveries open opportunities for developing EV-based biomarkers and neuroprotective therapies.

Transforming cancer research

Cancer research remained one of the most active domains represented at the meeting. Investigators described how tumor-derived EVs contribute to metastasis, immune evasion, drug resistance, and tumor microenvironment remodeling.

Novel therapeutic strategies included exosome-mediated delivery of chemotherapeutic agents, siRNAs, microRNAs, and gene-editing tools. Several groups reported promising results using engineered extracellular vesicles as precision delivery vehicles capable of targeting tumors while minimizing off-target effects. The integration of EVs into cancer immunotherapy was also highlighted as a rapidly advancing area.

Growing interest in plant-derived EVs

Beyond mammalian systems, TURSEV-26 revealed a striking expansion of interest in plant-derived and food-derived nanovesicles. Researchers reported the isolation and characterization of EVs from coffee, parsley, orange, lemon, celery, turmeric, grape, rosemary, pumpkin, bitter melon, berries, and other edible plants.

These vesicles were investigated for applications ranging from cancer therapy and wound healing to gut microbiome modulation and neuroprotection. The growing body of evidence suggests that naturally occurring plant vesicles may become important components of future functional foods, nutraceuticals, and regenerative health strategies.

The technological foundation supporting EV science was another important topic throughout the conference. Significant advances were presented in microfluidic EV isolation systems, nanoparticle tracking analysis, high-throughput characterization technologies, biosensors, molecularly imprinted polymers, and automated manufacturing platforms. Speakers emphasized that progress in analytical technologies is essential for enabling reproducible and clinically meaningful EV research.

Building scientific standards

At the same time, several speakers called for greater scientific rigor. Pakize Neslihan Candangelen and others emphasized that many studies still use the term “exosome” without sufficient evidence regarding vesicle origin and composition.

In line with international MISEV recommendations, researchers stressed the importance of standardized nomenclature, comprehensive characterization, and reproducible methodologies. The consensus was that future clinical success will depend not only on exciting biological discoveries but also on robust scientific standards.

NutriEV Project vision Featured at TURSEV-26

A particularly distinctive contribution was Seppo Vainio’s presentation, “High Tech Return to Nature via the Garden of EVe,” which offered a broader vision linking “NutriEVs” biology with natural ecosystems, regenerative health, citizen science, nutrition, and environmental communication networks. This perspective resonated strongly with the conference’s growing interest in plant-derived vesicles and the possibility that EV-mediated communication extends beyond conventional biomedical contexts into ecological and societal domains.

Taken together, TURSEV-26 demonstrated that EV research has entered a new phase. The field is no longer focused solely on understanding what EVs are; it is increasingly concerned with how they can be engineered, manufactured, measured, regulated, and applied to improve human health. The convergence of molecular biology, regenerative medicine, nanotechnology, artificial intelligence, and systems medicine is creating unprecedented opportunities for EV-based diagnostics and therapeutics.

The conference clearly showed that EVs are becoming a central platform for personalized, preventive, predictive, and regenerative medicine, positioning the field for significant scientific and clinical advances in the coming decade.